| An inhibitor of glycinamide ribonucleotide formyltransferase is selectively cytotoxic to cells that lack a functional G1 checkpoint. | |
| | |
MedLine Citation:
|
PMID: 9443639 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: We studied the effects of purine depletion on the cell cycle using a specific inhibitor of de novo purine biosynthesis, AG2034, an inhibitor of glycinamide ribonucleotide formyltransferase (GARFT). METHODS: Cytotoxicity was determined by clonogenic assays, and cell cycle perturbations by flow cytometry. Ribonucleotide pools were measured by anion exchange high-pressure liquid chromatography, and DNA strand-breaks were determined by alkaline elution and by the TUNEL assay. RESULTS: When cells were maintained in standard tissue culture medium, which contained 2.2 microM folic acid, AG2034 was cytostatic in all the cell lines tested. Under low-folate conditions (50 nM folic acid), AG2034 caused up to 50% cell death in cell lines that possessed a functional G1 checkpoint (A549, MCF-7), but was only cytostatic to the remaining cells, even at very high concentrations (100 microM). In contrast, AG2034 at 10 nM or 100 nM killed all the cells in cultures of HeLa/S3 or SW480 cells, which lack a functional G1 checkpoint. Flow cytometry studies indicated that in G1 checkpoint-competent cells, AG2034 caused a G1 arrest. Those cells (up to 50%) that were already in S phase died, but the cells that were in G1 arrest maintained viability, based upon clonogenic assays, for many days. In G1 checkpoint-deficient cells, no G1 arrest was seen after AG2034 treatment, all cells progressed into S phase, and all cells died. Measurement of DNA strand-breaks, either by alkaline elution or by the dUTP end-labelling technique, indicated no DNA strand-breaks 24 h after AG2034 treatment, indicating that purine nucleotide depletion can trigger the G1 checkpoint in the absence of DNA damage. CONCLUSION: Purine depletion causes slow cell death in cells that have passed the G1 checkpoint, but cytostasis in cells that are arrested at the G1 checkpoint. The GARFT inhibitor, at physiological folate concentrations, thus causes selective cytotoxicity to cells lacking a functional G1 checkpoint. |
| | |
Authors:
|
C C Zhang; T J Boritzki; R C Jackson |
Related Documents
:
|
68809 - Cell cycle phase recovery from bleomycin-induced potentially lethal damage. 8730839 - Expression of the neurofibromatosis 1 (nf1) gene during growth arrest. 6170499 - Proliferation kinetics of perturbed cell populations determined by the bromodeoxyuridin... 21821129 - Heterologous expression and purification of the soybean 7s globulin α' subunit extensi... 1577059 - Cell cycle-dependent regulation of cdw75 (beta-galactoside alpha-2,6-sialyltransferase)... 1702269 - Ethanol causes accelerated g1 arrest in differentiating hl-60 cells. 21054139 - Celecoxib and radioresistant glioblastoma-derived cd133(+) cells: improvement in radiot... 18228389 - Determining cell cycle stages by flow cytometry. 17520279 - Patterns of asexual reproduction in nannochloris bacillaris and marvania geminata (chlo... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Cancer chemotherapy and pharmacology Volume: 41 ISSN: 0344-5704 ISO Abbreviation: Cancer Chemother. Pharmacol. Publication Date: 1998 |
Date Detail:
|
Created Date: 1998-02-10 Completed Date: 1998-02-10 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 7806519 Medline TA: Cancer Chemother Pharmacol Country: GERMANY |
Other Details:
|
Languages: eng Pagination: 223-8 Citation Subset: IM |
Affiliation:
|
Agouron Pharmaceuticals, Inc., San Diego, CA 92121, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals DNA, Neoplasm / drug effects Enzyme Inhibitors / pharmacology* Folic Acid / administration & dosage, metabolism G1 Phase / drug effects Glutamates / pharmacology* Hela Cells / drug effects* Humans Hydroxymethyl and Formyl Transferases / antagonists & inhibitors* Mice Phosphoribosylglycinamide Formyltransferase Purines / biosynthesis* Pyrimidines / pharmacology* |
| Chemical | |
Reg. No./Substance:
|
0/AG 2034; 0/DNA, Neoplasm; 0/Enzyme Inhibitors; 0/Glutamates; 0/Purines; 0/Pyrimidines; 120-73-0/purine; 59-30-3/Folic Acid; EC 2.1.2.-/Hydroxymethyl and Formyl Transferases; EC 2.1.2.2/Phosphoribosylglycinamide Formyltransferase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Activity of gemcitabine in non-small-cell lung cancer: results of the Japan gemcitabine group (A) ph...
Next Document: Clinical effects and pharmacokinetics of the fusion protein PIXY321 in children receiving myelosuppr...